Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CC-312 in Systemic Lupus Erythematosus: NCT07177911 Clinical Landscape Report 2026
15 October 2026
NCT07177911 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gamgertamig in Relapse multiple myeloma: NCT07181239 Clinical Landscape Report 2026
15 October 2026
NCT07181239 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
QY-201 in Dermatitis, Atopic: NCT07180511 Clinical Landscape Report 2026
15 October 2026
NCT07180511 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TQB2934 in Multiple Myeloma: NCT07179679 Clinical Landscape Report 2026
15 October 2026
NCT07179679 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gemcitabine in Non-Muscle Invasive Bladder Neoplasms: NCT07184021 Clinical Landscape Report 2026
15 October 2026
NCT07184021 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Tofacitinib etocomil in Dermatitis, Atopic: NCT07182864 Clinical Landscape Report 2026
15 October 2026
NCT07182864 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Busulfan in Acute Myeloid Leukemia: NCT07183878 Clinical Landscape Report 2026
15 October 2026
NCT07183878 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Linvoseltamab-gcpt in Recurrent Multiple Myeloma: NCT07181941 Clinical Landscape Report 2026
15 October 2026
NCT07181941 clinical landscape for Recurrent Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital) in Multiple Myeloma: NCT07185477 Clinical Landscape Report 2026
15 October 2026
NCT07185477 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dupilumab in Severe Atopic Dermatitis: NCT07187089 Clinical Landscape Report 2026
15 October 2026
NCT07187089 clinical landscape for Severe Atopic Dermatitis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LW-402 in Dermatitis, Atopic: NCT07186387 Clinical Landscape Report 2026
15 October 2026
NCT07186387 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tofacitinib etocomil in Dermatitis, Atopic: NCT07185282 Clinical Landscape Report 2026
15 October 2026
NCT07185282 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.